Diagnostic And Consulting Center 1 Pernik EOOD
- Address
- Ulitsa Riga 3, 2304 Pernik, Bulgaria
Diagnostic And Consulting Center 1 Pernik EOOD
Diagnostic And Consulting Center 1 Pernik EOOD is a clinical research facility specializing in diverse therapeutic areas, with particular expertise in neurology, dermatology, respiratory medicine, and immunology. The center conducts Phase 3 trials evaluating innovative treatments for conditions affecting various patient populations, from dermatological disorders to complex neuropsychiatric conditions.
- Respiratory disorders including uncontrolled asthma and advanced inhaled corticosteroid combination therapies
- Neuropsychiatric conditions, particularly Alzheimer's disease-related symptoms such as agitation, psychosis, hallucinations, and delusions
- Dermatological and immunological conditions including nonsegmental vitiligo and chronic spontaneous urticaria
The center demonstrates comprehensive capabilities in evaluating both novel therapeutic agents and biosimilar products, with extensive experience in conducting placebo-controlled and active-controlled studies. Their research portfolio includes long-term safety evaluations and dose-optimization studies, reflecting their commitment to advancing treatment options across multiple medical specialties and contributing to the development of therapies that address significant unmet medical needs in various patient populations.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
- 1Maplight Therapeutics Inc.2active
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Maplight Therapeutics Inc.2trials
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 476 other sites in Bulgaria
Therapeutic Area Benchmark — Bulgaria
Select a therapeutic area to compare against other sites in Bulgaria.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Bulgaria
Market Share
Country: Bulgaria
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Diagnostic And Consulting Center 1 Pernik EOOD
lock Showing 1 of 8 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A 52-week, randomised, double blind, multicentre, 2-arm parallel group trial assessing the efficacy and safety of CHF6001 (total daily dose 3200 μg) Dry Powder Inhaler (DPI) add-on to maintenance medium or high dose inhaled corticosteroid in combination with long-acting ß2-agonists in subjects with uncontrolled asthma | Chiesi Farmaceutici S.p.A. | Phase II | Not Recruiting | Nov 2023 | Dec 2025 |
IMP list
lock Showing 1 of 9 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| 5-[(1R,5R)-3-AZABICYCLO[3.1.0]HEXAN-1-YL]-3-METHYL-1,2,4-OXADIAZOLE | 2 | Unknown | 2026-01-22 | 2026-07-03 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.